Toll-like receptors: New targets for multiple myeloma treatment?

Akesolo, Olaia; Buey, Berta; Beltrán‐Visiedo, Manuel; Giraldos, David; Marzo, Isabel; Latorre, Eva

doi:10.1016/j.bcp.2022.114992

Cited by 14 publications

(9 citation statements)

References 129 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TLR activation causes inflammatory responses, modulation of cell cycle, apoptosis, or regulation of cell metabolism. In multiple myeloma, TLRs signaling is dysregulated and the expression of TLR1, TLR2 and TLR6 seem to be higher in MM patients than in healthy donors and TLRs are suggested as future therapy targets in MM (Akesolo et al 2022), (Thakur et al 2015).…”

Section: Discussionmentioning

confidence: 99%

Comparison of Transcriptomic Changes in Younger and Older Multiple Myeloma Patients from the MMRF-CoMMpass Study RNA-Seq Data

Keskin

2022

Preprint

View full text Add to dashboard Cite

Background: Age-related differences in Multiple Myeloma (MM) are studied in clinical and genomic context, however, transcriptome changes have not yet been determined. The aim of this study is to identify the genes that are expressed differently in young and old patient groups and to examine the relationship of these genes with biological pathways and the drugs that can be used. Methods: The MMRF CoMMpass cohort RNA-Seq data (n=634) was used to analyze differen-tially expressed genes between young and old patients. GO term and KEGG gene-set enrichment analysis were conducted using R packages. Drug-gene interactions were detected using DGIdb. Results: Globally, 523 genes (366 upregulated, 157 downregulated) were differentially expressed (p < 0.05) in young patients. Totally 220 GO terms, mostly related to immune regulation path-ways were enriched. Cytokine-cytokine receptor interaction gene-set was enriched in KEGG GSEA. Among the highest expression difference, genes involved in immune regulation (FCGR1A, FCER1G, TLR2), known proto-oncogenic genes (BCL2, FGR) and genes under in-vestigation for association with various cancers (RGL4, MT-RNR1, ETS2, ENPP3, FUT7, NTNG2, PRAM1) were identified. Drugs associated with the pathways affected by these genes were identified. Conclusions: Further investigation of differentially expressed genes in young patients may shed light on new treatment options.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Transcriptomic Changes in Younger and Older Multiple Myeloma Patients from the MMRF-CoMMpass Study RNA-Seq Data

Keskin

2022

Preprint

View full text Add to dashboard Cite

show abstract

“…This indicates the role of Toll-like 4 in regulating the organism's defence against infection. This was indicated by Akesolo et al, (2022) in their study that activating the receptors leads to enhancing the immunity and resistance of organisms against many diseases that can infect them in certain environmental conditions.…”

Section: Effect Of Beta-amino Butyric Acid (Baba) On 4 Receptorsmentioning

confidence: 98%

“…Monitor-like receptors (TLRs) are essential immune receptors with the ability to recognize conserved molecular patterns expressed by pathogens and damaged cells (Kashani et al, 2021). Activation of TLRs can lead to a range of effects including in ammatory responses, cell cycle modi cation, apoptosis, or regulation of cell metabolism (Akesolo et al, 2022;Fitzgerald and Kagan, 2020). TLRs are an evolutionarily ancient family of pattern recognition receptors (Fitzgerald and Kagan, 2020).…”

Section: Introductionmentioning

confidence: 99%

Effect of non-protein amino acids β-amino butyric acid (BABA) on the intestinal G- bacterial community

Al-Dulaimy

Jasim

2022

Preprint

View full text Add to dashboard Cite

This study was conducted in the animal house of the College of Education for Girls, to investigate the effect of beta-amino butyric acid (BABA) on the microorganisms in the digestive system of mice. The bacteria present in the stool were isolated and diagnosed. And that intestinal bacteria have an effective role in influencing human health. However, few factors that affect the bacteria in the digestive system are known. Despite the increase in the number of microbial communities colonizing the gastrointestinal tract, many of these bacteria have been found to possess virulence factors that can negatively affect the host organism and protect it from prevailing antibiotics. BABA) was used with four treatments (100, 200, 300, 0) mg/kg animal weight denoted by A, B, C, and D. Male rats were immersed orally in four doses per week, and the results showed that the amino acid effectively affected On the intestinal bacterial community, where the third concentration of the fourth dose gave the lowest rate of the number of bacterial isolates, which led to the elimination of a large number of them, followed by the second concentration and then the first compared to the comparison treatment that achieved the highest rate of the number of isolates. While histidine had no negative effect on the Toll-Like Receptor 4 (TLR4), the results showed that TLR4 was a normal receptor.

show abstract

“…TLRs were proclaimed to have been found on freshly isolated myeloma cells and the MM cell lines, with their expression being notably higher than in normal plasma cells [ 96 , 99 , 100 , 101 ]. TLR-specific ligands induce intensified proliferation, endurance, cytokine and chemokine excretion, induction of apoptosis or protection from it, drug resistance, and the immune escape of the MM cell lines, in some measure due to autocrine interleukin-6 production [ 96 , 102 ].…”

Section: Toll-like Receptors and Hematologymentioning

confidence: 99%

“…Human myeloma cell lines (HMCL) express a broad range of TLRs at the gene and protein levels, with TLR1, TLR4, TLR7, TLR8, and TLR9 being the most detectable [ 99 , 100 ]. Novel studies found TLR7 to be the most frequently expressed of all the TLRs in the MM cell lines, with some of its ligands such as loxoribine and R848 inhibiting apoptosis and promoting the proliferation of cell survival [ 101 ].…”

Section: Toll-like Receptors and Hematologymentioning

confidence: 99%

The Role of TRL7/8 Agonists in Cancer Therapy, with Special Emphasis on Hematologic Malignancies

et al. 2023

View full text Add to dashboard Cite

Toll-like receptors (TLR) belong to the pattern recognition receptors (PRR). TLR7 and the closely correlated TLR8 affiliate with toll-like receptors family, are located in endosomes. They recognize single-stranded ribonucleic acid (RNA) molecules and synthetic deoxyribonucleic acid (DNA)/RNA analogs—oligoribonucleotides. TLRs are primarily expressed in hematopoietic cells. There is compiling evidence implying that TLRs also direct the formation of blood cellular components and make a contribution to the pathogenesis of certain hematopoietic malignancies. The latest research shows a positive effect of therapy with TRL agonists on the course of hemato-oncological diseases. Ligands impact activation of antigen-presenting cells which results in production of cytokines, transfer of mentioned cells to the lymphoid tissue and co-stimulatory surface molecules expression required for T-cell activation. Toll-like receptor agonists have already been used in oncology especially in the treatment of dermatological neoplastic lesions. The usage of these substances in the treatment of solid tumors is being investigated. The present review discusses the direct and indirect influence that TLR7/8 agonists, such as imiquimod, imidazoquinolines and resiquimod have on neoplastic cells and their promising role as adjuvants in anticancer vaccines.

show abstract

Toll-like receptors: New targets for multiple myeloma treatment?

Cited by 14 publications

References 129 publications

Comparison of Transcriptomic Changes in Younger and Older Multiple Myeloma Patients from the MMRF-CoMMpass Study RNA-Seq Data

Comparison of Transcriptomic Changes in Younger and Older Multiple Myeloma Patients from the MMRF-CoMMpass Study RNA-Seq Data

Effect of non-protein amino acids β-amino butyric acid (BABA) on the intestinal G- bacterial community

The Role of TRL7/8 Agonists in Cancer Therapy, with Special Emphasis on Hematologic Malignancies

Contact Info

Product

Resources

About